Dr. Kowalski is an HRB funded Emerging Investigator for Health, a Funded Investigator at the APC Microbiome Ireland, and a Senior lecturer in advanced therapies at the School of Pharmacy, University College Cork. He received his Master’s degree in Biochemistry in 2009 from Jagiellonian University, Poland. He then moved to the Netherlands to earn his PhD from Groningen University, focusing on the development of lipid-based systems for selective delivery of siRNA to inflamed endothelium. Subsequently, he received his postdoctoral training at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology in the laboratories of Prof. Daniel Anderson and Prof. Robert Langer. His multidisciplinary research focused on engineering novel biomaterials to enable the delivery of messenger RNAs to treat inflammatory diseases, cancer, and diabetes. After his postdoc, Dr. Kowalski joined an early-stage biotechnology company, Senda Bioscience, Inc., where he gained experience in the development and commercialization of next-generation nano-medicines. Dr. Kowalski has been the recipient of several international scholarships and awards and his work resulted in a number of high-impact publications, the co-invention of several patents on RNA delivery technologies, and the creation of a US-based biotech startup (Orna therapeutic Inc.). He has recently won a highly prestigious European Research Council (ERC) Starting Grant to elucidate the therapeutic potential of the new class of circular RNAs.
Theme: Microbes to Molecules
SDGs: Good health and wellbeing - Development of sustainable strategies for enhancing the quality of advanced pharmaceutical products aimed at high medical need diseases
Research key words: nanotechnology, drug delivery, biomaterials engineering, gene therapy, pharmabiotics